• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: CAREFUSION ALARIS PUMP MODULE ADMINISTRATION SET; SET, ADMINISTRATION, INTRAVASCULAR

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

CAREFUSION ALARIS PUMP MODULE ADMINISTRATION SET; SET, ADMINISTRATION, INTRAVASCULAR Back to Search Results
Model Number 10010453
Device Problems Fluid/Blood Leak (1250); Material Separation (1562)
Patient Problem Blood Loss (2597)
Event Date 01/25/2020
Event Type  malfunction  
Manufacturer Narrative
Although requested, product has not been received.A follow up report will be submitted with failure investigation results should the device be received for evaluation.Per previous discussion with the customer, it is their policy not to provide patient demographics.
 
Event Description
It was reported that the tubing separated at filter while total parenteral nutrition (tpn) was infusing through iv pump.The tpn was programmed to infuse 1,200ml over 24 hours through central venous line and the event occurred 4 hours into infusion.The patient lost some amount of blood and the tpn bag had to be discarded, which led to interruption on the patient's nutrition intake.There was no patient injury and no additional medical intervention required.It was then reported that the patient received subsequent tpn infusion 12 hours after the event.Although requested, additional information was not provided.
 
Event Description
It was reported that the tubing separated at filter while total parenteral nutrition (tpn) was infusing through the iv pump.The (tpn) was programmed to infuse 1at ,200ml over (24) hours through central venous line and the event occurred (4) hours into infusion.The patient lost some amount of blood and the (tpn) bag had to be discarded, which led to an interruption on the patient's nutrition intake.There was no patient injury and no additional medical intervention required.It was then reported that the patient received subsequent (tpn) infusion (12) hours after the event.Although requested, additional information was not provided.
 
Manufacturer Narrative
Additional information provided: d.10.The customer's report that the tubing separated from the filter and leaked was confirmed.Visual inspection of the set noted separation at the engagement of the outlet of the adult micron filter and expected pvc tubing sleeve.The rest of the expected components below the filter were not received for evaluation.No other obvious issues were observed.Testing was deemed unnecessary due to separation.The cause of the leak was due to the noted separation.The root cause of the separation was not identified.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ALARIS PUMP MODULE ADMINISTRATION SET
Type of Device
SET, ADMINISTRATION, INTRAVASCULAR
Manufacturer (Section D)
CAREFUSION
10020 pacific mesa blvd
san diego CA 92121 4386
MDR Report Key9716785
MDR Text Key190049048
Report Number9616066-2020-00472
Device Sequence Number1
Product Code FPA
UDI-Device Identifier07613203021135
UDI-Public7613203021135
Combination Product (y/n)N
PMA/PMN Number
K944320
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type company representative,foreig
Type of Report Initial,Followup
Report Date 01/27/2020
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received02/17/2020
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Expiration Date07/21/2022
Device Model Number10010453
Device Catalogue Number10010453
Device Lot Number19076460
Was Device Available for Evaluation? Device Returned to Manufacturer
Date Returned to Manufacturer03/05/2020
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
Treatment
8100,8015, THERAPY DATE (B)(6) 2020.
-
-